Purine analogues as kinase inhibitors

A review

Sahil Sharma, Samir Mehndiratta, Sunil Kumar, Jagjeet Singh, Preet M.S. Bedi, Kunal Nepali

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Protein kinases constitute one of the largest and most functionally diverse gene families that regulate key cell functions. In past several years, kinase inhibition has emerged as potential anti-cancer drug target. Purine is a priveleged heterocyclicnucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogues in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. In the past decade, purine analogues have emerged as significantly potent kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2- aminopurine, purvalanol-A, seleciclib, FSBA, adenosine thiol analogue possessing purine as the basic moiety fall under this category. In view of the use of purines for the inhibition of kinases, there is need for compilation of data specifying the prominence of purines in the treatment of cancer through this mechanism. The structure of the potent compounds, their IC50 values, models used and the enzymes/ receptors/ targets involved have been presented in this review. The present compilation covers the patents published entailing the purines as kinase inhibitors and the purine drugs employed in chemotherapy.

Original languageEnglish
Pages (from-to)308-341
Number of pages34
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume10
Issue number3
DOIs
Publication statusPublished - Oct 1 2015
Externally publishedYes

Fingerprint

Purines
Phosphotransferases
Patents
2-Aminopurine
Pentostatin
Vidarabine
Ganciclovir
Acyclovir
Bronchodilator Agents
Azathioprine
Immunosuppressive Agents
Theophylline
Caffeine
Sulfhydryl Compounds
Pharmaceutical Preparations
Adenosine
Protein Kinases
Inhibitory Concentration 50
Antiviral Agents
Neoplasms

Keywords

  • Chemotherapy
  • Clinical trials
  • Patents
  • Potential inhibitors
  • Protein kinases
  • Purines

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Purine analogues as kinase inhibitors : A review. / Sharma, Sahil; Mehndiratta, Samir; Kumar, Sunil; Singh, Jagjeet; Bedi, Preet M.S.; Nepali, Kunal.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 10, No. 3, 01.10.2015, p. 308-341.

Research output: Contribution to journalReview article

Sharma, Sahil ; Mehndiratta, Samir ; Kumar, Sunil ; Singh, Jagjeet ; Bedi, Preet M.S. ; Nepali, Kunal. / Purine analogues as kinase inhibitors : A review. In: Recent Patents on Anti-Cancer Drug Discovery. 2015 ; Vol. 10, No. 3. pp. 308-341.
@article{75a9d7464c464440b2431932cdbe3026,
title = "Purine analogues as kinase inhibitors: A review",
abstract = "Protein kinases constitute one of the largest and most functionally diverse gene families that regulate key cell functions. In past several years, kinase inhibition has emerged as potential anti-cancer drug target. Purine is a priveleged heterocyclicnucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogues in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. In the past decade, purine analogues have emerged as significantly potent kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2- aminopurine, purvalanol-A, seleciclib, FSBA, adenosine thiol analogue possessing purine as the basic moiety fall under this category. In view of the use of purines for the inhibition of kinases, there is need for compilation of data specifying the prominence of purines in the treatment of cancer through this mechanism. The structure of the potent compounds, their IC50 values, models used and the enzymes/ receptors/ targets involved have been presented in this review. The present compilation covers the patents published entailing the purines as kinase inhibitors and the purine drugs employed in chemotherapy.",
keywords = "Chemotherapy, Clinical trials, Patents, Potential inhibitors, Protein kinases, Purines",
author = "Sahil Sharma and Samir Mehndiratta and Sunil Kumar and Jagjeet Singh and Bedi, {Preet M.S.} and Kunal Nepali",
year = "2015",
month = "10",
day = "1",
doi = "10.2174/1574892810666150617112230",
language = "English",
volume = "10",
pages = "308--341",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Purine analogues as kinase inhibitors

T2 - A review

AU - Sharma, Sahil

AU - Mehndiratta, Samir

AU - Kumar, Sunil

AU - Singh, Jagjeet

AU - Bedi, Preet M.S.

AU - Nepali, Kunal

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Protein kinases constitute one of the largest and most functionally diverse gene families that regulate key cell functions. In past several years, kinase inhibition has emerged as potential anti-cancer drug target. Purine is a priveleged heterocyclicnucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogues in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. In the past decade, purine analogues have emerged as significantly potent kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2- aminopurine, purvalanol-A, seleciclib, FSBA, adenosine thiol analogue possessing purine as the basic moiety fall under this category. In view of the use of purines for the inhibition of kinases, there is need for compilation of data specifying the prominence of purines in the treatment of cancer through this mechanism. The structure of the potent compounds, their IC50 values, models used and the enzymes/ receptors/ targets involved have been presented in this review. The present compilation covers the patents published entailing the purines as kinase inhibitors and the purine drugs employed in chemotherapy.

AB - Protein kinases constitute one of the largest and most functionally diverse gene families that regulate key cell functions. In past several years, kinase inhibition has emerged as potential anti-cancer drug target. Purine is a priveleged heterocyclicnucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogues in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. In the past decade, purine analogues have emerged as significantly potent kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2- aminopurine, purvalanol-A, seleciclib, FSBA, adenosine thiol analogue possessing purine as the basic moiety fall under this category. In view of the use of purines for the inhibition of kinases, there is need for compilation of data specifying the prominence of purines in the treatment of cancer through this mechanism. The structure of the potent compounds, their IC50 values, models used and the enzymes/ receptors/ targets involved have been presented in this review. The present compilation covers the patents published entailing the purines as kinase inhibitors and the purine drugs employed in chemotherapy.

KW - Chemotherapy

KW - Clinical trials

KW - Patents

KW - Potential inhibitors

KW - Protein kinases

KW - Purines

UR - http://www.scopus.com/inward/record.url?scp=84947740920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947740920&partnerID=8YFLogxK

U2 - 10.2174/1574892810666150617112230

DO - 10.2174/1574892810666150617112230

M3 - Review article

VL - 10

SP - 308

EP - 341

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 3

ER -